Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

Journal of the National Cancer Institute

Volumn 89, Issue 21, 1997, Pages 1586-1594

  Lode, Holger N ^a   Xiang, Rong ^a   Varki, Nissi M ^b   Dolman, Carrie S ^a   Gillies, Stephen D ^c   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fuji ImmunoPharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW METASTASIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SCREENING; DRUG TARGETING; FEMALE; LIVER METASTASIS; MINIMAL RESIDUAL DISEASE; MOUSE; NEUROBLASTOMA; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030690067     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.21.1586     Document Type: Article

References (40)

1. Brodeur GH, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-81.
2. Brodeur GH, Pritchard J, Berthold F, Carlsen NL, Castel V, Castleberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis: staging and response to treatment. J Clin Oncol 1993;11:1466-77.
3. Niethammer D, Handgretinger R. Clinical strategies for the treatment of neuroblastoma. Eur J Cancer 1995;31A:568-71.
4. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31 A: 261-7.
5. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody l4.G2a. Cancer Immunol Immunother 1992;35:199-204.
6. Cheung NK, Cheung IY, Canete A, Yeh SJ, Kushner B, Bonilla MA, et al. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res 1994;54:2228-33.
7. Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatriccancer patients. Cancer Immunol Immunother 1995;41:29-36.
8. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci U S A 1986;83:7893-7.
9. Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 1987;138:1992-8.
10. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokineactivated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
11. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 1983;157: 884-97.
12. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990; 50:5234-9.
13. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
14. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
15. Favrot MC, Floret D, Negrier S, Cochat P, Bouffet E, Zhou DC, et al. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 1989;4:499-503.
16. Frost JD, Hank JA, Reaman GH, Frierdich SR, Seeger RC, Gan J, et al. Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997;80:317-33.
17. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
18. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994;91:9626-30.
19. Pancook JD, Becker JC, Gillies SD, Reisfeld RA. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother 1996;42:88-92.
20. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A 1996; 93:2702-07.
21. Greene LA, Shain W, Chalazonitis A, Breakfield X, Minna J, Coon HG, et al. Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells. Proc Natl Acad Sci U S A 1975;72:4923-7.
22. Leonard MP, Gearhart JP, Jeffs RD. Chemoimmunotherapy in conjunction with surgery: strategies for management of murine neuroblastoma. J Pediatr Surg 1991;26:1224-9.
23. Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region casettes. J Immunol Methods 1989;125:191-202.
24. Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A 1992;89:1428-32.
25. Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, et al. Activation of human effector cells by a tumor reactive recombinant antiganglioside GD2 interleukin-2 fusion protein (ch14.18-IL-2). Clin Cancer Res 1996;2:1951-9.
26. Mueller BM, Reisfeld RA, Gillies SD. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci U S A 1990;87:5702-5.
27. Ehrlich P. Croonian lecture. Proc R Soc London 1900;66:424-37.
28. Mueller BM, Romerdahl CA, Trent JM,. Reisfeld RA. Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res 1991;51:2193-8.
29. Fowler C, Zimmer C, Boghaert E, Thomas M, Zimmer S. Metastasis of C1300 and TBJ murine neuroblastonias correlates with expression of matrix metalloproteinases. Cancer Lett 1995;93:171-7.
30. Hutchinson R, Fligiel S, Appleyard J, Varani J, Wicha M. Attachment of neuroblastoma cells to extracellular matrix: correlation with metastatic capacity. J Lab Clin Med 1989;113:561-8.
31. Iwakawa M, Ando K, Ohkawa H, Koike S, Chen Y. A murine model for bone marrow metastasis established by an i.v. injection of C-1300 neuroblastoma in A/J mice. Clin Exp Metastasis 1994;12:231-7.
32. Burchill SA, Bradbury FM, Selby P, Lewis IJ. Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Eur J Cancer 1995;31A: 553-6.
33. Miyajima Y, Horibe K, Fukuda M, Matsumoto K, Numata S, Mori H, et al. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1996; 77:1214-9.
34. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1995;75:2757-61.
35. Burchill SA, Bradbury FM, Smith B, Lewis IJ, Selby P. Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer 1994;57:671-5.
36. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996;183:2361-6.
37. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci U S A 1996;93: 7826-31.
38. Raulet DH. Recognition events that inhibit and activate natural killer cells. Curr Opin Immunol 1996;8:372-7.
39. Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell 1995;82:697-700.
40. Kos FJ, Engleman EG. Requirement for natural killer cells in the induction of cytotoxic T cells. J Immunol 1995;155:578-84.